Drug Trial Radar · NCT07911579
A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Dec 30, 2028
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, dose-escalation and dose expansion, and cohort-expansion phase Ib/II clinical study to evaluate the safety and antitumor efficacy of SYH2051 in combination with Irinotecan Hydrochloride Liposome Injection in Patients with Advanced Solid Tumors.
Conditions
- Advanced Solid Tumors
Interventions
SYH2051Drug
SYH2051 is an oral medication taken once daily, with dosage selected according to the dose group.
Irinotecan Hydrochloride Liposome.Drug
Irinotecan Hydrochloride Liposome is administered by intravenous infusion every 2 weeks (Q2W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: From Day 1 to Day 28
- Frequency and severity of AETime frame: From Day 1 to 12 months.
- Maximal tolerable dose (MTD)Time frame: From Day 1 to 12 months.
- Recommended phase 2 dose (RP2D)Time frame: From Day 1 to 12 months.
- ORRTime frame: From Day 1 to 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.